InvestWiser
Enzymatica publ AB
ENZY · Nasdaq Stockholm · Healthcare
1.79SEK
+3.2%last day
Price as of 2 October 2026
Performance
1 month
−11.4%
1 year
−23.8%
3 years, per year
−16.3%
5 years, per year
−29.3%
Largest fall, 3 years
−86.8%
Below the peak now
−94.5%
Volatility, 1 year
64.4%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
4.3
Dividend yield
0.0%
Return on equity
−46.7%
Net margin
−88.3%
Market value
43 m USD
Quality, value and trend
Where Enzymatica stands against every Nordic stock today. 100 is best.
74
Profitability and a sound balance sheet over time. Better than 74% of Nordic stocks.
8
The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.
11
The price development over the past year. Better than 11% of Nordic stocks.
15
Quality, value and trend together. Better than 15% of Nordic stocks.
About Enzymatica
Enzymatica publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 18 employees.
Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis